Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
Prarthna V Bhardwaj1, Yara G Abdou2
1Division of Hematology-Oncology, University of Massachusetts Chan School of Medicine - Baystate, Springfield, USA.
Current Oncology Reports
|October 18, 2022
Summary
Germline genetic testing for breast cancer is advancing, impacting clinical care and systemic therapy options. Understanding these genetic mutations, like those targeted by PARP inhibitors, is crucial for improved patient outcomes.
Area of Science:
- Oncology
- Genetics
- Clinical Medicine
Background:
- 5-10% of breast cancer patients have hereditary cancer susceptibility gene variants.
- Germline mutations significantly impact patient management and treatment strategies.
- Traditional testing focused on screening and risk reduction.
Purpose of the Study:
- Discuss advances in germline genetic testing for breast cancer.
- Highlight limitations and clinical care impacts of genetic testing.
- Update on therapeutic implications of germline mutations.
Main Methods:
- Review of recent literature on germline genetic testing.
- Analysis of therapeutic implications of germline mutations.
- Discussion of systemic therapy options for breast cancer.
Main Results:
- Germline genetic results now have significant systemic therapy implications.
- Oral poly-ADP-ribose polymerase (PARP) inhibitors offer targeted treatment options.
- Advances necessitate a paradigm shift in genetic testing models.
Conclusions:
- Germline genetic testing is crucial for personalized breast cancer treatment.
- Targeted therapies, like PARP inhibitors, improve outcomes.
- Increased demand for genetic testing requires evolving testing models.
Keywords:
BRCA1BRCA2Breast cancerGermline genetic testingOlaparibPARP inhibitorsSystemic therapyTargeted therapiesMore Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K